Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oncopeptides AB Year-end report 2017

Thu, Feb 22, 2018 08:00 CET

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the Year-end report 2017.“With increasing clinical data the possible role for Ygalo® in helping patients with myeloma becomes clearer” SUMMARY OF Q4 October 1st – December 31st 2017 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 66.7 (loss: 51.1) MSEK · Loss per share, before and after dilution, was 1.68 (loss: 1.84) SEK · On December 31st cash and cash equivalents amounted to 404.1 (40.3) MSEK Significant events during the period October 1st to December 31st 2017 ·

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Oncopeptides AB Year-end report 2017

Subscribe

Media